Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)

Conditions:   Gastric Neoplasms;   Gastroesophageal Junction Adenocarcinoma
Interventions:   Biological: Pembrolizumab;   Biological: Placebo;   Drug: Cisplatin;   Drug: 5-FU;   Drug: Oxaliplatin;   Drug: Capecitabine;   Drug: S-1;   Biological: Trastuzumab
Sponsor:   Merck Sharp & Dohme Corp.
Not yet recruiting

https://ift.tt/2Mfy5Jq